Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NBE-Therapeutics

Explore full profile

Focused on developing next-generation antibody-drug conjugates for cancer treatment

Basel, SwitzerlandFounded 2012Biotech & Life Sciences
Valuation $1–2.5B Last recorded · 2020
Revenue $10–50M Latest reported FY
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for NBE-Therapeutics and the history behind them.

About NBE-Therapeutics

NBE-Therapeutics is a biotechnology company, acquired by Boehringer Ingelheim in 2020, that specializes in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company was founded in 2012 and is based in Basel, Switzerland.

NBE-Therapeutics has a proprietary platform for developing what it calls immune-stimulatory ADCs (iADCs). These are designed to target and kill tumor cells while also stimulating the patient's immune system to fight the cancer. The company's business model is focused on advancing its product candidates through preclinical and early clinical development before partnering with larger pharmaceutical companies for late-stage development and commercialization.

Source: Dealroom company data

At a glance

Founded
2012
Headquarters
Basel, Switzerland
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierColt$25–100M revenue

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom
Market map
Market map Top Swiss Deep Tech startups

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

  • Boehringer Ingelheim Venture Fund
  • The Commission for Technology and Innovation - CTI
  • European Commission

Series A2 investors entered at this stage

  • PPF Group
  • Novo Holdings

Series B and later1 investor entered at this stage

  • Boehringer Ingelheim

Talent

Book a demo to see the people
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇭 Switzerland80.6%
🇩🇪 Germany13.9%
🇫🇷 France5.6%
3 countries shown
Web traffic by country
1.3K monthly visits
across markets
🇨🇭 Switzerland61.5%
🇩🇪 Germany30.8%
🇫🇷 France15.4%
Top 3 markets shown

Patents

Estimated portfolio value
$30M

14 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NBE-Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NBE-Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles